CUV
CLINUVEL PHARMACEUTICALS LIMITED
$8.17
▲ +1.87%
Market cap
$412M
Turnover
$902,578
Last price
$8.17
Day change
+1.87%
Announcements
12
Range, past year
Open 11.48 · Low 7.930 · Now 8.170 · High 14.00
Open CUV in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CUV momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
28/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
+1.9%
1 Week
-1.0%
1 Month
-3.5%
1 Year
-27.7%
RSI
41
Avg daily range
3.8%
CLINUVEL PHARMACEUTICALS LIMITED scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -26.4%
- Risk rating: High
- Composite downside risk elevated
CUV announcements
Recent price-sensitive releases.
- 2026-08-27 CLINUVEL considers Nasdaq listing, ASX delisting Company Administration - Other
- 2026-08-27 Investor Presentation Company Presentation | Preliminary Final Report
- 2026-08-27 A decade of profitability provides U.S. expansion foundation Preliminary Final Report
- 2026-08-27 Appendix 4E and Annual Report to Shareholders 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report | Dividend Record Date | Dividend Rate
- 2026-07-30 Commercial update on vitiligo Progress Report
- 2026-07-28 Update - SCENESSE in vitiligo Progress Report
- 2026-07-23 CLINUVEL strategic reorganisation to refocus on U.S. markets
More Health Care stocks
Most traded in the same sector.